Included in the formulation
АТХ:N.05.A.E.04 Ziprasidone
Pharmacodynamics:In the central nervous system predominantly blocks dopamine D2-receptors and serotonin 5-HT2A receptors, as well as H1-gistaminovye and α1-adrenoceptors of the brain, due to which eliminates negative symptoms in patients with schizophrenia (poverty of speech, introversion, flattening of emotions). Does not interact with m1-cholinoreceptors, in this connection does not affect cognitive functions.
Pharmacokinetics:After oral administration, up to 60% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 6-8 hours, with intramuscular injection - after 1 hour. The connection with plasma proteins is 99%.
Metabolism in the liver.
The half-life is 6.6 hours. Elimination by the kidneys and with feces.
Indications:It is used to treat all forms of schizophrenia, arrest psychomotor agitation in patients with schizophrenia.
V.F20-F29.F20 Schizophrenia
V.F20-F29.F21 Chrysotile disorder
V.F20-F29.F22 Chronic delusional disorders
V.F20-F29.F25 Schizoaffective disorder
V.F20-F29.F29 Inorganic psychosis, unspecified
Contraindications:Interval lengthening QT, arrhythmias, cardiac decompensated failure, myocardial infarction, individual intolerance, children under 18 years of age.
Carefully:Severe renal insufficiency, increased propensity to convulsions, bradycardia, elderly age over 65 years.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, with food, initial dose: 40 mg twice a day. Then the dose is increased to 80 mg twice a day for 3 days.
Intramuscularly, with psychomotor agitation: 10 mg every 2 hours and 20 mg every 24 hours.
The highest daily dose: 160 mg for oral administration, 40 mg for intramuscular injection.
The highest single dose: 80 mg.
Side effects:Central and peripheral nervous system: asthenia, akathisia, dystonia, dizziness, insomnia or drowsiness, convulsions, tremors, dyskinesia.
The cardiovascular system: tachycardia, orthostatic hypotension, lengthening of the interval QT.
Digestive system: weight gain, dry mouth, constipation, nausea.
Dermatological reactions: a rash.
Sense organs: blurred vision.
Reproductive system: reversible hyperprolactinemia.
Allergic reactions.
Overdose:Increased side effects.
Treatment is symptomatic.
Interaction:Strengthens the effects of drugs that depress the central nervous system.
Ketoconazole and carbamazepine increase the concentration of ziprasidone.
Incompatible with ethanol.
Solution for intramuscular injection pharmacologically incompatible with other drugs and solutions, except distilled water.
Special instructions:In the treatment it is not recommended to drive vehicles and work with moving mechanisms.